RESUMEN
Rationale: Chronic obstructive pulmonary disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or bacterial infection. Early identification of exacerbation triggers is important to guide appropriate therapy, but currently available tests are slow and imprecise. Volatile organic compounds (VOCs) can be detected in exhaled breath and have the potential to be rapid tissue-specific biomarkers of infection etiology. Objectives: To determine whether volatile organic compound measurement could distinguish viral from bacterial infection in COPD. Methods: We used serial sampling within in vitro and in vivo studies to elucidate the dynamic changes that occur in VOC production during acute respiratory viral infection. Highly sensitive gas chromatography-mass spectrometry techniques were used to measure VOC production from infected airway epithelial-cell cultures and in exhaled breath samples from healthy subjects experimentally challenged with rhinovirus (RV)-A16 and from subjects with COPD with naturally occurring exacerbations. Measurements and Main Results: We identified a novel VOC signature comprising decane and other long-chain alkane compounds that is induced during RV infection of cultured airway epithelial cells and is also increased in the exhaled breath from healthy subjects experimentally challenged with RV and from patients with COPD during naturally occurring viral exacerbations. These compounds correlated with the magnitude of antiviral immune responses, viral burden, and exacerbation severity but were not induced by bacterial infection, suggesting that they represent a specific virus-inducible signature. Conclusions: Our study highlights the potential for measurement of exhaled breath VOCs as rapid, noninvasive biomarkers of viral infection. Further studies are needed to determine whether measurement of these signatures could be used to guide more targeted therapy with antibiotic/antiviral agents for COPD exacerbations.
Asunto(s)
Biomarcadores/análisis , Pruebas Respiratorias/métodos , Diagnóstico Precoz , Infecciones por Picornaviridae/diagnóstico , Infecciones por Picornaviridae/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Compuestos Orgánicos Volátiles/análisis , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
COVID-19 , Personal Militar , Infecciones por Picornaviridae , Ageusia , Anosmia , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/fisiopatología , Tos , Humanos , Salud Militar , Faringitis , Infecciones por Picornaviridae/diagnóstico , Infecciones por Picornaviridae/fisiopatología , Estudios Retrospectivos , Rhinovirus , SARS-CoV-2 , Virosis/diagnóstico , Virosis/fisiopatologíaRESUMEN
Rationale: Rhinovirus (RV) C can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing.Objectives: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses.Methods: Longitudinal data from the COAST (Childhood Origins of Asthma) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for RV-A and RV-C (three types each) were determined using a novel PCR-based assay. Data were pooled from 14 study cohorts in the United States, Finland, and Australia, and mixed-effects logistic regression was used to identify factors related to the proportion of RV-C versus RV-A detection.Measurements and Main Results: In COAST, RV-A and RV-C infections were similarly common in infancy, whereas RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (P < 0.001, χ2) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5-27%) at the age of 2 years, but by the age of 16 years, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A; P < 0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (P < 0.0001), CDHR3 genotype (P < 0.05), and wheezing illnesses (P < 0.05). Furthermore, certain RV types (e.g., C2, C11, A78, and A12) were consistently more virulent and prevalent over time.Conclusions: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.
Asunto(s)
Anticuerpos Neutralizantes/sangre , Asma/fisiopatología , Susceptibilidad a Enfermedades , Infecciones por Picornaviridae/fisiopatología , Ruidos Respiratorios/fisiopatología , Rhinovirus/genética , Rhinovirus/patogenicidad , Adolescente , Factores de Edad , Asma/epidemiología , Asma/virología , Australia/epidemiología , Niño , Preescolar , Estudios de Cohortes , Femenino , Finlandia/epidemiología , Variación Genética , Genotipo , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Masculino , Infecciones por Picornaviridae/epidemiología , Infecciones por Picornaviridae/inmunología , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Children with a history of rhinovirus (RV) positive bronchiolitis have a high risk of developing subsequent asthma. Maternal asthma might also increase this risk. The aim of this study was to investigate the combined effects of hospitalization for RV positive bronchiolitis in infancy and a history of maternal asthma on the development of asthma at preschool age. METHODS: This is a prospective cohort study of 139 preschool-aged children, with a history of hospital admission for bronchiolitis in infancy, followed-up to ascertain asthma and asthma-like symptoms, skin prick allergy test positivity, and lung function measured pre- and post-bronchodilator using impulse oscillometry. RESULTS: Children with a past hospitalization for RV positive bronchiolitis (42.4% of all) and a history of maternal asthma (36.7% of all) had the greatest prevalence and risk ratio (RR) for doctor-diagnosed asthma (prevalence 81.8% and RR 2.10, 95% confidence interval [CI] 1.37-3.19, p = .001), use of inhaled corticosteroids (68.2% and RR 2.17, 95% CI 1.19-3.99, p = .001) and short-acting ß-agonists in the last 12 months (95.2% and RR 1.49, 95% CI 1.17-1.89, p = .001), as compared to those with RV negative bronchiolitis and no maternal asthma history. More children in this group had an abnormal airway resistance (33.3% and adjusted risk ratio [aRR] 3.11, 95% CI 1.03-9.47, p = .045) and reactance (27.8% and aRR 2.11, 95% CI 1.06-4.26, p = .035) at 5 Hz, as compared to those with RV negative bronchiolitis and no maternal asthma history. CONCLUSION: Hospitalization for RV positive bronchiolitis in early life combined with a history of maternal asthma identifies a subgroup of children with a high asthma burden while participants with only one of the two risk factors had intermediate risk for asthma.
Asunto(s)
Asma/epidemiología , Bronquiolitis/epidemiología , Infecciones por Picornaviridae/epidemiología , Rhinovirus , Asma/fisiopatología , Bronquiolitis/fisiopatología , Preescolar , Femenino , Hospitalización , Humanos , Lactante , Pulmón/fisiopatología , Masculino , Madres , Oportunidad Relativa , Infecciones por Picornaviridae/fisiopatología , Estudios Prospectivos , Pruebas de Función Respiratoria , Factores de RiesgoRESUMEN
In this review, we discuss the latest developments in research pertaining to virus-induced asthma exacerbations and consider recent advances in treatment options. Asthma is a chronic disease of the airways that continues to impose a substantial clinical burden worldwide. Asthma exacerbations, characterised by an acute deterioration in respiratory symptoms and airflow obstruction, are associated with significant morbidity and mortality. These episodes are most commonly triggered by respiratory virus infections. The mechanisms underlying the pathogenesis of virus-induced exacerbations have been the focus of extensive biomedical research. Developing a robust understanding of the interplay between respiratory viruses and the host immune response will be critical for developing more efficacious, targeted therapies for exacerbations. CONCLUSION: There has been significant recent progress in our understanding of the mechanisms underlying virus-induced airway inflammation in asthma and these advances will underpin the development of future clinical therapies.
Asunto(s)
Antiasmáticos/uso terapéutico , Antivirales/uso terapéutico , Asma/tratamiento farmacológico , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Virosis/tratamiento farmacológico , Infecciones por Adenovirus Humanos/tratamiento farmacológico , Infecciones por Adenovirus Humanos/inmunología , Infecciones por Adenovirus Humanos/fisiopatología , Administración por Inhalación , Asma/inmunología , Asma/fisiopatología , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/fisiopatología , Progresión de la Enfermedad , Humanos , Gripe Humana/tratamiento farmacológico , Gripe Humana/inmunología , Gripe Humana/fisiopatología , Interferón beta/uso terapéutico , Macrólidos/uso terapéutico , Omalizumab/uso terapéutico , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/inmunología , Infecciones por Paramyxoviridae/fisiopatología , Infecciones por Picornaviridae/tratamiento farmacológico , Infecciones por Picornaviridae/inmunología , Infecciones por Picornaviridae/fisiopatología , Infecciones por Virus Sincitial Respiratorio/tratamiento farmacológico , Infecciones por Virus Sincitial Respiratorio/inmunología , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Infecciones del Sistema Respiratorio/inmunología , Infecciones del Sistema Respiratorio/fisiopatología , Virosis/inmunología , Virosis/fisiopatologíaRESUMEN
Human rhinoviruses have been linked both to the susceptibility of asthma development and to the triggering of acute exacerbations. Given that the human airway epithelial cell is the primary site of human rhinovirus (HRV) infection and replication, the current review focuses on how HRV-induced modulation of several aspects of epithelial cell phenotype could contribute to the development of asthma or to the induction of exacerbations. Modification of epithelial proinflammatory and antiviral responses are considered, as are alterations in an epithelial barrier function and cell phenotype. The contributions of the epithelium to airway remodeling and to the potential modulation of immune responses are also considered. The potential interactions of each type of HRV-induced epithelial phenotypic changes with allergic sensitization and allergic phenotype are also considered in the context of asthma development and of acute exacerbations.
Asunto(s)
Asma/virología , Células Epiteliales/virología , Infecciones por Picornaviridae/virología , Rhinovirus/fisiología , Asma/fisiopatología , Bronquios/citología , Bronquios/virología , Células Epiteliales/inmunología , Humanos , Fenotipo , Infecciones por Picornaviridae/fisiopatología , Rhinovirus/inmunologíaRESUMEN
BACKGROUND: Human coronaviruses (HCoVs) have been recognized as causative agents of respiratory tract infections.Our aim was to describe HCoV infections in hospitalized children in a prospective surveillance study for 14 years and compare them with other respiratory viruses. METHODS: As a part of an ongoing prospective study to identify the etiology of viral respiratory infections in Spain, we performed the analysis of HCoV infections in children hospitalized in a secondary hospital in Madrid, between October 2005 and June 2018. Clinical data of HCoV patients were compared with those infected by rhinovirus, respiratory syncytial virus and influenza. RESULTS: The study population consisted of 5131 hospitalizations for respiratory causes in children. A total of 3901 cases (75.9%) had a positive viral identification and 205 cases (4.1%) were positive for HCoV. Only 41 cases (20%) of HCoV infection were detected as single infections. Episodes of recurrent wheezing were the most common diagnosis, and 112 children (54%) had hypoxia. Clinical data in HCoV cases were similar to those associated with rhinovirus; however, patients with HCoV were younger. Other viruses were associated with hypoxia more frequently than cases with HCoV; high fever was more common in influenza infections and bronchiolitis in respiratory syncytial virus group. Although a slight peak of circulation appears mostly in winter, HCoV has been detected throughout the year as well. CONCLUSIONS: HCoV infections represent a small fraction of respiratory infections that require hospitalization in children and their characteristics do not differ greatly from other respiratory viral infections.
Asunto(s)
Bronquiolitis Viral/epidemiología , Infecciones por Coronavirus/epidemiología , Hospitalización , Neumonía Viral/epidemiología , Adolescente , Distribución por Edad , Betacoronavirus , Bronquiolitis Viral/fisiopatología , Bronquiolitis Viral/virología , COVID-19 , Niño , Preescolar , Infecciones por Coronavirus/fisiopatología , Infecciones por Coronavirus/virología , Coronavirus Humano NL63 , Coronavirus Humano OC43 , Femenino , Fiebre/fisiopatología , Humanos , Hipoxia/fisiopatología , Lactante , Recién Nacido , Gripe Humana/epidemiología , Gripe Humana/fisiopatología , Gripe Humana/virología , Masculino , Coronavirus del Síndrome Respiratorio de Oriente Medio , Pandemias , Infecciones por Picornaviridae/epidemiología , Infecciones por Picornaviridae/fisiopatología , Infecciones por Picornaviridae/virología , Neumonía Viral/fisiopatología , Neumonía Viral/virología , Estudios Prospectivos , Ruidos Respiratorios/fisiopatología , Infecciones por Virus Sincitial Respiratorio/epidemiología , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Infecciones por Virus Sincitial Respiratorio/virología , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/fisiopatología , Infecciones del Sistema Respiratorio/virología , Rhinovirus , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo , SARS-CoV-2 , Estaciones del Año , Síndrome Respiratorio Agudo Grave , Índice de Severidad de la Enfermedad , España/epidemiologíaRESUMEN
Objective Epidemic myalgia associated with human parechovirus type 3 (EM-HPeV3) is characterized by severe muscle pain and weakness on the limbs and trunk with a fever. No outbreak of EM-HPeV3 has been reported since 2016, and its clinical characteristics have not been sufficiently clarified. We herein report a series of EM-HPeV3 cases during the summer of 2019 and clarify the clinical characteristics of EM-HPeV3. Methods The diagnosis of EM-HPeV3 was established when the patients met both of the following criteria: (1) Patients developed severe muscle pain and weakness with a fever within a week, and those symptoms resolved within a month; and (2) HPeV3 was detected in either a throat swab or fecal specimen of the patient by polymerase chain reaction. We reviewed the medical records of these patients retrospectively. Results Seven patients met the criteria (6 men and 1 woman, age 34 to 47 years old). Myalgia was observed on the thigh, lower legs, upper arms, and forearms in seven, five, two, and five patients, respectively. Four patients showed distal dominant weakness on the arms, while none of the patients showed proximal dominant weakness on the arms. Of the six patients examined, five showed reduced tendon reflexes on all four limbs. One patient showed slight myogenic change and increased insertion activities on needle electromyography. Conclusion We observed seven cases of EM-HPeV3 during the summer of 2019. Reduced tendon reflexes and distal dominancy of muscle pain and weakness on the arms are considered its distinct clinical features.
Asunto(s)
Mialgia/epidemiología , Mialgia/fisiopatología , Infecciones por Picornaviridae/epidemiología , Infecciones por Picornaviridae/fisiopatología , Pleurodinia Epidémica/epidemiología , Pleurodinia Epidémica/fisiopatología , Pleurodinia Epidémica/virología , Adulto , Brotes de Enfermedades , Femenino , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Estudios RetrospectivosAsunto(s)
Encéfalo/fisiopatología , Infecciones por Coronavirus/fisiopatología , Infecciones por Picornaviridae/fisiopatología , Neumonía Viral/fisiopatología , Betacoronavirus , Encéfalo/diagnóstico por imagen , COVID-19 , Prueba de COVID-19 , Vacunas contra la COVID-19 , Técnicas de Laboratorio Clínico , Coinfección , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/metabolismo , Electroencefalografía , Enterovirus , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Pandemias , Infecciones por Picornaviridae/complicaciones , Infecciones por Picornaviridae/diagnóstico , Infecciones por Picornaviridae/metabolismo , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/metabolismo , Polipéptido alfa Relacionado con Calcitonina/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , SARS-CoV-2RESUMEN
BACKGROUND: Parechovirus (PeV)-A3 and enteroviruses (EV) are the most common viruses causing sepsis and meningoencephalitis in neonates and young infants. Clinical manifestations of PeV-A3 infection are more severe than those of EV infection, and no pleocytosis with a positive polymerase chain reaction (PCR) result for PeV-A3 in cerebrospinal fluid (CSF) are characteristic findings. We hypothesized that innate immune responses to PeV-A3 and EV are distinct in serum and CSF. METHODS: We evaluated 22 cytokines/chemokines in serum and CSF from PeV-A3- or EV-infected patients younger than 4 months in Niigata, Japan, from 2015 through 2018. Infection was diagnosed with real-time PCR followed by sequencing. Febrile neonates and infants with sepsis-like syndrome who had negative bacterial culture and viral PCR for both PeV-A and EV were also included (non-PeV-A/EV patients). RESULTS: Among 192 febrile patients, we evaluated 16 PeV-A3-infected, 15 EV-infected, and 8 non-PeV-A/EV patients. Serum pro-/anti-inflammatory cytokine/chemokine levels were higher in PeV-A3-infected patients than in EV-infected patients (P < .02). Although most cytokine/chemokine were elevated in CSF from EV-infected patients, levels were low or undetectable in PeV-A3-infected and non-PeV-A/EV patients (P < .001). CONCLUSIONS: Distinct cytokine/chemokine patterns in serum and CSF may explain the different clinical manifestations of PeV-A3-infected and EV-infected neonates and young infants.
Asunto(s)
Citocinas/metabolismo , Infecciones por Enterovirus/diagnóstico , Enterovirus/inmunología , Parechovirus/inmunología , Infecciones por Picornaviridae/diagnóstico , Líquido Cefalorraquídeo/virología , Enterovirus/genética , Infecciones por Enterovirus/fisiopatología , Femenino , Fiebre/etiología , Humanos , Inmunidad Innata , Lactante , Recién Nacido , Japón , Masculino , Meningoencefalitis/virología , Parechovirus/genética , Infecciones por Picornaviridae/fisiopatología , Sepsis/virología , Suero/virologíaRESUMEN
Although recent guidelines recommend a minimalist approach to bronchiolitis, there are several issues with this posture. First, there are concerns about the definition of the disease, the quality of the guidelines, the method of administration of bronchodilators, and the availability of tools to evaluate the response to therapies. Second, for decades it has been assumed that all cases of viral bronchiolitis are the same, but recent evidence has shown that this is not the case. Distinct bronchiolitis phenotypes have been described, with heterogeneity in clinical presentation, molecular immune signatures and clinically relevant outcomes such as respiratory failure and recurrent wheezing. New research is critically needed to refine viral bronchiolitis phenotyping at the molecular and clinical levels as well as to define phenotype-specific responses to different therapeutic options.
Asunto(s)
Bronquiolitis Viral/tratamiento farmacológico , Bronquiolitis Viral/fisiopatología , Broncodilatadores/uso terapéutico , Ruidos Respiratorios/fisiopatología , Péptidos Catiónicos Antimicrobianos/inmunología , Bronquiolitis Viral/inmunología , Bronquiolitis Viral/virología , Dermatitis Atópica/inmunología , Eosinofilia/sangre , Adhesión a Directriz , Hospitalización , Humanos , Microbiota/inmunología , Fenotipo , Infecciones por Picornaviridae/tratamiento farmacológico , Infecciones por Picornaviridae/inmunología , Infecciones por Picornaviridae/fisiopatología , Guías de Práctica Clínica como Asunto , Infecciones por Virus Sincitial Respiratorio/tratamiento farmacológico , Infecciones por Virus Sincitial Respiratorio/inmunología , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Virus Sincitial Respiratorio Humano , Rhinovirus , Células Th2/inmunología , CatelicidinasRESUMEN
Asthma is a dynamic disease, in which lung mechanical and inflammatory processes interact in a complex manner, often resulting in exaggerated physiological, in particular, inflammatory responses to exogenous triggers. We hypothesize that this may be explained by respiratory disease-related systems instability and loss of adaptability to changing environmental conditions, manifested in highly fluctuating biomarkers and symptoms. Using time series of inflammatory (eosinophils, neutrophils, FeNO), clinical and lung function biomarkers (PEF, FVC,FEV1), we estimated this loss of adaptive capacity (AC) during an experimental rhinovirus infection in 24 healthy and asthmatic human volunteers. Loss of AC was estimated by comparing similarities between pre- and post-challenge time series. Unlike healthy participants, the asthmatic's post-viral-challenge state resembled more other rhinovirus-infected asthmatics than their own pre-viral-challenge state (hypergeometric-test: p=0.029). This reveals loss of AC and supports the concept that in asthma, biological processes underlying inflammatory and physiological responses are unstable, contributing to loss of control.
Asunto(s)
Adaptación Fisiológica/fisiología , Asma/fisiopatología , Pulmón/fisiopatología , Infecciones por Picornaviridae/fisiopatología , Adulto , Asma/virología , Femenino , Humanos , Pulmón/virología , Masculino , Infecciones por Picornaviridae/virología , Estudios Prospectivos , Pruebas de Función Respiratoria , Rhinovirus/fisiología , Adulto JovenRESUMEN
Human parechovirus (HPeV), particularly type 3 (HPeV3), is an important cause of sepsis-/meningitis-like illness in young infants. Laboratory records identified a total of ten HPeV-positive cases in Southeastern Australia between January and July 2019. The HPeV present in these cases were typed by Sanger sequencing of the partial viral capsid protein 1 (VP1) region and selected cases were further characterised by additional Sanger or Ion Torrent near-full length virus sequencing. In seven of the ten cases, an HPeV type 5 (HPeV5) was identified, and in the remaining three cases, an HPeV type 1 was identified. The HPeV5-positive cases were infants under the age of 3 months admitted to hospital with fever, rash, lethargy and/or sepsis-like clinical signs. Near full-length virus sequencing revealed that the HPeV5 was most likely a recombinant virus, with structural genes most similar to an HPeV5 from Belarus in 2018, and a polymerase gene most similar to an HPeV3 from Australia in 2013/14. While HPeV5 is not typically associated with severe clinical signs, the HPeV5 identified here may have been able to cause more severe disease in young infants through the acquisition of genes from a more virulent HPeV.
Asunto(s)
Parechovirus/genética , Parechovirus/aislamiento & purificación , Infecciones por Picornaviridae/epidemiología , Infecciones por Picornaviridae/virología , Sepsis/virología , Australia/epidemiología , Proteínas de la Cápside , Genotipo , Secuenciación de Nucleótidos de Alto Rendimiento , Hospitalización , Humanos , Lactante , Recién Nacido , Filogenia , Infecciones por Picornaviridae/clasificación , Infecciones por Picornaviridae/fisiopatología , Recombinación Genética , Estudios Retrospectivos , Secuenciación Completa del GenomaRESUMEN
Viral respiratory tract infections have been implicated as the predominant risk factor for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). We aimed to evaluate, longitudinally, the association between upper respiratory tract infections (URTI) caused by viruses and AECOPD.Detection of 18 viruses was performed in naso- and orοpharyngeal swabs from 450 COPD patients (Global Initiative for Chronic Obstructive Lung Disease stages 2-4) who were followed for a mean of 27â months. Swabs were taken during stable periods (n=1909), at URTI onset (n=391), 10â days after the URTI (n=356) and during an AECOPD (n=177) and tested using a multiplex nucleic acid amplification test.Evidence of at least one respiratory virus was significantly higher at URTI onset (52.7%), 10â days after the URTI (15.2%) and during an AECOPD (38.4%), compared with the stable period (5.3%, p<0.001). During stable visits, rhinovirus accounted for 54.2% of all viral infections, followed by coronavirus (20.5%). None of the viruses were identified in two consecutive stable visits. Patients with a viral infection at URTI onset did not have a higher incidence of exacerbation than patients without viral infection (p=0.993). Τhe incidence of any viral infection during an AECOPD was similar between URTI-related AECOPD and non-URTI-related AECOPD (p=0.359). Only 24% of the patients that had a URTI-related AECOPD had the same virus at URTI onset and during an AECOPD. Detection of parainfluenza 3 at URTI onset was associated with a higher risk of an AECOPD (p=0.003). Rhinovirus and coronavirus were the most frequently detected viruses during AECOPD visits, accounting for 35.7% and 25.9% of all viral infections, respectively.The prevalence of viral infection during the stable period of COPD was low. The risk of exacerbation following the onset of URTI symptoms depends on the particular virus associated with the event and was significant only for parainfluenza 3.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Virosis/epidemiología , Infecciones por Adenovirus Humanos/epidemiología , Infecciones por Adenovirus Humanos/fisiopatología , Anciano , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/fisiopatología , Coinfección , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/fisiopatología , ADN Viral , Supervivencia sin Enfermedad , Femenino , Humanos , Gripe Humana/epidemiología , Gripe Humana/fisiopatología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa Multiplex , Nasofaringe , Infecciones por Paramyxoviridae/epidemiología , Infecciones por Paramyxoviridae/fisiopatología , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/fisiopatología , Infecciones por Picornaviridae/epidemiología , Infecciones por Picornaviridae/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , ARN Viral , Infecciones por Virus Sincitial Respiratorio/epidemiología , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Infecciones del Sistema Respiratorio/fisiopatología , Factores de Tiempo , Virosis/fisiopatologíaRESUMEN
BACKGROUND: Parechovirus and enterovirus belong to a family of Picornaviridae, non- enveloped, small-sized RNA viruses, responsible for multiple human diseases. Recent introduction of molecular tests enabled the identi cation of parechovirus and enterovirus infections. Our aim was a retrospective analysis of signs and symptoms associated with confirmed parechovirus or enterovirus infections among children treated in the Department of Neonatology, St. Louis Regional Children's Hospital in Kraków, Poland. METHODS: Based on laboratory records, we identified all cases of parecho- or enterovirus infections confirmed by identification of viral RNA in nasal swab or cerebrospinal fluid samples. Hospital records and laboratory tests results of selected patients were then analyzed, and selected data were summarized, with emphasis on clinical and laboratory findings at admission. RESULTS: We identified 11 cases of parechovirus and three of enterovirus infections. All cases were neonates admitted to hospital with fever and irritability. Except for leukopenia in 50% of patients, no significant abnormalities were noted in blood counts and serum biochemistry, including low C-reactive protein and procalcitonin. In nine cases, cerebrospinal fluid was collected, the fluid protein concentrations and cell counts were moderately increased. Final diagnosis was meningitis in 12 children, and other viral infections in two. CONCLUSIONS: Viral infection, including parecho- and enteroviruses, should be considered in the etiology of fever and meningitis in neonates. The available molecular tests allow for detection of viral genetic material even in a scant biological specimen collected from neonates.
Asunto(s)
Infecciones por Enterovirus/fisiopatología , Meningitis Viral/fisiopatología , Infecciones por Picornaviridae/fisiopatología , Infecciones por Enterovirus/diagnóstico , Infecciones por Enterovirus/metabolismo , Femenino , Fiebre , Hospitales Pediátricos , Humanos , Recién Nacido , Leucopenia , Masculino , Meningitis Viral/diagnóstico , Meningitis Viral/metabolismo , Cavidad Nasal , Parechovirus , Infecciones por Picornaviridae/diagnóstico , Infecciones por Picornaviridae/metabolismo , ARN Viral/líquido cefalorraquídeo , ARN Viral/metabolismo , Estudios RetrospectivosRESUMEN
INTRODUCTION: Prenatal exposure to maternal psychological distress (PD) may have programming effects on the fetus/infant hypothalamic-pituitary-adrenal (HPA) axis and subsequently on the development of the fetus' immune function. Therefore, our aim was to study whether prenatal exposure to PD is related to early infant HPA axis reactivity in the context of a subclinical rhinovirus infection that challenges infants HPA axis postnatally. METHODS: This study included 336 10-week-old infants from the nested case control Focus Cohort of the FinnBrain Birth Cohort Study. The outcome was infant HPA axis reactivity in a stress test. The acute stressor comprised of pediatric examination with venipuncture and nasal swabs for virus assessment. Saliva cortisol samples were collected at 5 time points: baseline, 0, 15, 25 and 35 min after the stressor. HPA axis reactivity was defined by the cumulative post-stressor cortisol concentration. RESULTS: HPA axis reactivity was blunted in the PD/rhinovirus + group compared to the average of control/rhinovirus+, PD/rhinovirus-, and control/rhinovirus- groups (difference: 14.7 ln [nmol/L] × min, 95% confidence interval 3.8-25.6, p = .008). HPA axis reactivity was significantly blunted only in boys with rhinovirus detected when separately tested for boys and girls (p = .04). CONCLUSION: Our finding of PD-exposed rhinovirus-positive infants having blunted cortisol secretion gives rise to a hypothesis that maternal PD during pregnancy influences infant HPA axis functioning and the functioning of the immune system. Future studies are needed to test whether this suppression of the HPA axis that co-occurs with rhinovirus infection associates with later disease development (e.g., asthma).
Asunto(s)
Hidrocortisona/análisis , Infecciones por Picornaviridae/metabolismo , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Adulto , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Humanos , Hidrocortisona/metabolismo , Sistema Hipotálamo-Hipofisario/fisiopatología , Lactante , Recién Nacido , Masculino , Infecciones por Picornaviridae/fisiopatología , Sistema Hipófiso-Suprarrenal/fisiopatología , Embarazo , Rhinovirus/patogenicidad , Saliva/química , Estrés Psicológico/fisiopatologíaRESUMEN
BACKGROUND: Enteroviruses (EV) and parechoviruses (PeV) are ubiquitous viruses that cause a range of illness, including acute illness in children aged <1 year. OBJECTIVES: We describe EV and PeV infections among children from 2 US study sites aged <1 year and hospitalized with acute infections. For EV- and PeV-negative case-patients, we explored other viral etiologies. METHODS: Participants were aged <1 year, hospitalized during 2016, and had cerebrospinal fluid (CSF) collected for routine diagnostic testing. Demographic and clinical data were abstracted from medical charts, and residual specimens were sent to CDC for confirmatory testing and typing. RESULTS: Of 472 eligible case-patients, CSF specimen was available for 319 (67.6%). Among those, 13 (4.1%) were positive for EV and 11 (3.4%) for PeV. Most case-patients (86.8%, n = 277) were aged <2 months, as were all EV- or PeV-positive case-patients. None of the positive case-patients had underlying conditions, and the chief complaint for 91.7% (n = 22) was fever. Twelve positive case-patients were admitted to intensive care (ICU) and had brief hospital stays (median 2 days). Sequencing revealed a variety of EV types and the predominance of PeV-A3 among the PeV-positive case-patients. CONCLUSIONS: A range of EV and PeV types were associated with acute febrile illnesses leading to hospitalization in children aged <2 months. Approximately half of EV and PeV case-patients were admitted to ICU, but length of hospital stay was brief and illnesses were generally self-limiting. Clinicians should consider EV and PeV infections in infants presenting with febrile illness.
Asunto(s)
Enterovirus/aislamiento & purificación , Parechovirus/aislamiento & purificación , Infecciones por Picornaviridae/virología , Enfermedad Aguda , Líquido Cefalorraquídeo/virología , Enterovirus/clasificación , Enterovirus/genética , Femenino , Fiebre/diagnóstico , Fiebre/patología , Fiebre/fisiopatología , Fiebre/virología , Hospitalización , Humanos , Lactante , Recién Nacido , Masculino , Técnicas de Diagnóstico Molecular , Parechovirus/clasificación , Parechovirus/genética , Picornaviridae/clasificación , Picornaviridae/genética , Picornaviridae/aislamiento & purificación , Infecciones por Picornaviridae/diagnóstico , Infecciones por Picornaviridae/patología , Infecciones por Picornaviridae/fisiopatología , ARN Viral/análisisRESUMEN
This multicenter prospective cohort study describes the impact of human parechovirus meningitis on gross-motor neurodevelopment of young children. Gross-motor function was measured using Alberta Infant Motor Scale. Of a total of 38 eligible children < 10 months of age at onset, nine cases had clinical evidence of meningitis and polymerase chain reaction positive for human parechovirus in cerebrospinal fluid; 11 had no meningitis and polymerase chain reaction positive for human parechovirus in nasopharyngeal aspirate, blood, urine, or feces; and in 18, no pathogen was identified (reference group).The children with human parechovirus meningitis showed more frequent albeit not statistically significant suspect gross-motor function delay (mean Z-score (standard deviation) - 1.69 (1.05)) than children with human parechovirus infection-elsewhere (- 1.38 (1.51)). The reference group did not fall in the range of suspect gross-motor function delay (- 0.96 (1.07)). Adjustment for age at onset and maternal education did not alter the results.Conclusion: Six months after infection, children with human parechovirus meningitis showed more frequent albeit not statistically significant suspect gross-motor function delay compared to the population norm and other two groups. Longitudinal studies in larger samples and longer follow-up periods are needed to confirm the impact and persistence of human parechovirus meningitis on neurodevelopment in young children. What is Known: ⢠Human parechovirus is progressively becoming a major viral cause of meningitis in children. ⢠There is keen interest in the development of affected infants with human parechovirus meningitis. What is New: ⢠This study describes prospectively gross-motor functional delay in children with both clinical evidence of meningitis and polymerase chain reaction positive for human parechovirus in cerebrospinal fluid. ⢠It shows the importance of screening young children for developmental delay in order to refer those with delay for early intervention to maximize their developmental potential.
Asunto(s)
Discapacidades del Desarrollo/etiología , Meningitis Viral/complicaciones , Infecciones por Picornaviridae/complicaciones , Estudios de Casos y Controles , Discapacidades del Desarrollo/virología , Humanos , Lactante , Meningitis Viral/fisiopatología , Parechovirus , Infecciones por Picornaviridae/fisiopatología , Estudios Prospectivos , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Fecal samples from 27 pigs were longitudinally analyzed for Teschovirus A (TV-A), Sapelovirus A (SV-A), and Enterovirus G (EV-G) RNA presence. Suckling piglet fecal samples were negative for the three enteric picornaviruses. However, these picornaviruses were detected in 22/27 weaned pig fecal samples. This study provides new data on TV-A, SV-A, and EV-G infection dynamics.
Asunto(s)
Infecciones por Enterovirus/veterinaria , Enterovirus Porcinos/aislamiento & purificación , Heces/virología , Infecciones por Picornaviridae/veterinaria , Picornaviridae/aislamiento & purificación , Enfermedades de los Porcinos/virología , Teschovirus/aislamiento & purificación , Animales , Infecciones por Enterovirus/fisiopatología , Infecciones por Enterovirus/virología , Enterovirus Porcinos/clasificación , Enterovirus Porcinos/genética , Femenino , Estudios Longitudinales , Masculino , Filogenia , Picornaviridae/clasificación , Picornaviridae/genética , Infecciones por Picornaviridae/fisiopatología , Infecciones por Picornaviridae/virología , Porcinos , Enfermedades de los Porcinos/fisiopatología , Teschovirus/clasificación , Teschovirus/genética , DesteteRESUMEN
Enterovirus (EV) and Parechovirus (HPeV) are a frequent cause of infection in children. This review gives an overview of possible causes for differences in clinical presentation. EV and HPeV can cause a meningitis with or without pleocytosis. Different possible mechanisms for meningitis without pleocytosis are given. Little is known about the prognosis and long-term effects of EV and HPeV meningitis in children. Only some studies with a small number of children with EV or HPeV meningitis are reported. The different possible mechanisms involved in the neurological outcome after EV or HPeV meningitis will be discussed.